Azurity Pharmaceuticals has sued Massachusetts drug company Bionpharma, claiming that its generic of Azurity’s Epaned product infringes on a brand new patent.
AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.
Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
Bayer Healthcare and drug importer Meda Pharmaceuticals have sued generic manufacturer Apotex, alleging that its planned generic nasal spray infringes on Bayer’s Astepro patents.
Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.
A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.
Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.
Pfizer subsidiary Anacor has filed five lawsuits targeting drug manufacturers looking to manufacture generic versions of its eczema treatment Eucrisa.
Veterinary drug maker Dechra’s generic of a drug that treats vomiting in dogs and cats, Cerenia, infringes a patent owned by its competitor Zoetis, a new lawsuit has alleged.
Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.